|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Sean McLoughlin, GlaxoSmithKline

S

Sean McLoughlin

Product director, diabetes franchise, GlaxoSmithKline

BORN IN: Belfast, Ireland

PEOPLE ARE: "Your long term strategic advantage"

On the tough times ahead:

In five or 10 years, some companies will be here and some will not—and it is the leadership of the company that will determine that. The irony is that it will require a lot of investment in both capital and human resources to be successful at a time when maybe those investments are more likely to drop. It is going to take courage to figure out just what are the key issues, where the company needs to go, and then make those expenditures into the long term health of the company.

Sean McLoughlin

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Nancy Phelan, Wyeth

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.